Protagonist Therapeutics Inc (NASDAQ: PTGX) on Monday, soared 4.21% from the previous trading day, before settling in for the closing price of $53.0. Within the past 52 weeks, PTGX’s price has moved between $32.50 and $60.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -138.16%. With a float of $58.35 million, this company’s outstanding shares have now reached $61.93 million.
In an organization with 126 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 99.28%, operating margin of 13.1%, and the pretax margin is 27.47%.
Protagonist Therapeutics Inc (PTGX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Protagonist Therapeutics Inc is 5.86%, while institutional ownership is 102.51%. The most recent insider transaction that took place on Jun 10 ’25, was worth 570,300. In this transaction Chief Medical Officer of this company sold 10,000 shares at a rate of $57.03, taking the stock ownership to the 83,892 shares. Before that another transaction happened on Jun 09 ’25, when Company’s Chief Medical Officer sold 10,000 for $55.51, making the entire transaction worth $555,100. This insider now owns 83,892 shares in total.
Protagonist Therapeutics Inc (PTGX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.54 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -138.16% per share during the next fiscal year.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Trading Performance Indicators
Protagonist Therapeutics Inc (PTGX) is currently performing well based on its current performance indicators. A quick ratio of 17.26 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.47. Likewise, its price to free cash flow for the trailing twelve months is 10.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.76, a number that is poised to hit -0.58 in the next quarter and is forecasted to reach -0.18 in one year’s time.
Technical Analysis of Protagonist Therapeutics Inc (PTGX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.69 million. That was inferior than the volume of 0.99 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 60.96%.
During the past 100 days, Protagonist Therapeutics Inc’s (PTGX) raw stochastic average was set at 80.04%, which indicates a significant increase from 74.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.10 in the past 14 days, which was lower than the 2.18 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $49.93, while its 200-day Moving Average is $44.86. However, in the short run, Protagonist Therapeutics Inc’s stock first resistance to watch stands at $56.05. Second resistance stands at $56.87. The third major resistance level sits at $58.34. If the price goes on to break the first support level at $53.77, it is likely to go to the next support level at $52.30. The third support level lies at $51.48 if the price breaches the second support level.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Key Stats
Market capitalization of the company is 3.42 billion based on 61,982K outstanding shares. Right now, sales total 434,430 K and income totals 275,190 K. The company made 28,320 K in profit during its latest quarter, and -11,660 K in sales during its previous quarter.
